DiscoverBreast Cancer UpdateHR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

Update: 2025-10-14
Share

Description

Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment